NCT02852395 is a Phase 1 clinical trial of JNJ-48816274 in Healthy, sponsored by Janssen-Cilag International NV.

Who is sponsoring NCT02852395?

NCT02852395 is sponsored by Janssen-Cilag International NV.

What drugs are being tested in NCT02852395?

Interventions in NCT02852395: JNJ-48816274, Placebo.

Is NCT02852395 still recruiting?

NCT02852395 is currently completed. Last updated 27 April 2025.

Last reviewed 2025-04-27 · How we verify

NCT02852395

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-48816274

Completed Phase 1 Last updated 27 April 2025

What this trial tests

Phase 1 trial testing JNJ-48816274 in Healthy in 90 participants. Completed in 2 May 2018.

Timeline

13 August 2016

Primary endpoint
2 May 2018

2 May 2018

Quick facts

Lead sponsor	Janssen-Cilag International NV
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	90
Start date	13 August 2016
Primary completion	2 May 2018
Estimated completion	2 May 2018
Sites	2 locations across United Kingdom

Drugs / interventions tested

JNJ-48816274 — full drug profile →
Placebo

Conditions studied

Healthy — all drugs for Healthy →

Sponsor

Janssen-Cilag International NV — full company profile →

Who can join

18 and older, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a 3-part study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of JNJ-48816274 in healthy participants after administration of single and repeated doses, and to evaluate its potential effectiveness for treating insomnia.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effects of the selective orexin-2 receptor antagonist JNJ-48816274 on sleep initiated in the circadian wake maintenance zone: a randomised trial.
Revell VL, Della Monica C, Mendis J, Hassanin H, et al · · 2022 · cited 7× · PMID 34628482 · DOI 10.1038/s41386-021-01175-3

Verify or expand the search:

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other Janssen-Cilag International NV trials

Trials by the same sponsor.

NCT04940039 — A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings · Phase 4 · completed
NCT04338321 — A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selectiv · Phase 3 · completed
NCT03852160 — A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Stan · Phase 3 · withdrawn
NCT03947814 — A Study of Orally Administered Pimodivir in Adult Participants With Renal Impairment · Phase 1 · terminated
NCT03816631 — A Study of Orally Administered Pimodivir in Adult Participants With Hepatic Impairment · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02852395 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Janssen-Cilag International NV
Last refreshed: 27 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02852395.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing